Daiichi, GSK India Units To Join In Promoting Japan Makers’ Drugs
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo India Pharma and GlaxoSmithKline India plan a joint operation to promote the Japanese subsidiary's Benicar (olmesartan medoxomil) drug for treating hypertension. The deal for marketing Daiichi's $2 billion drug also includes promotion of the Japanese firm's combination products. Earlier, the U.K.-based GSK reached a similar agreement with Japan's Astellas to market its Mycamine (micafungin), all part of GSK's strategy of in-licensing products in high-growth therapeutic areas. The deal with GSK India also gives Daiichi an entry into the Indian market, which Daiichi Sankyo India plans to exploit. (Click here for more